Showing results (811-820 of 6,303) with videos related to

Sort By:
Pageof 631
Diabetes, Obesity & Metabolism|January 30, 2018
Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysisYe-Xuan Cao, Hui-Hui Liu, Qiu-Ting Dong, et al.
Diabetes, Obesity & Metabolism|August 29, 2017
Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta-analysis of randomized controlled trialsYumo Zhao, Lubin Xu, Dongli Tian, et al.
Diabetes, Obesity & Metabolism|January 18, 2018
Intra- and inter-subject variability for increases in serum ketone bodies in patients with type 2 diabetes treated with the sodium glucose co-transporter 2 inhibitor canagliflozinDavid Polidori, Hiroaki Iijima, Maki Goda, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Effects of exenatide once weekly plus dapagliflozin, exenatide once weekly, or dapagliflozin, added to metformin monotherapy, on body weight, systolic blood pressure, and triglycerides in patients with type 2 diabetes in the DURATION-8 studySerge A Jabbour, Juan P Frías, Cristian Guja, et al.
Diabetes, Obesity & Metabolism|January 10, 2018
Long-term safety and efficacy of tofogliflozin as add-on to insulin in patients with type 2 diabetes: Results from a 52-week, multicentre, randomized, double-blind, open-label extension, Phase 4 study in Japan (J-STEP/INS)Yasuo Terauchi, Masahiro Tamura, Masayuki Senda, et al.
Diabetes, Obesity & Metabolism|May 19, 2022
Nonalcoholic fatty liver disease and osteoporosis: A potential association with therapeutic implicationsIlias D Vachliotis, Athanasios D Anastasilakis, Antonis Goulas, et al.
Diabetes, Obesity & Metabolism|May 23, 2022
Mediators of ertugliflozin effects on heart failure and kidney outcomes among patients with type 2 diabetes mellitusMatthew W Segar, Ahmed A Kolkailah, Robert Frederich, et al.
Diabetes, Obesity & Metabolism|May 13, 2022
Interindividual variability in average glucose-glycated haemoglobin relationship in type 1 diabetes and implications for clinical practiceYongjin Xu, Richard M Bergenstal, Timothy C Dunn, et al.
Diabetes, Obesity & Metabolism|May 13, 2022
Efficacy and safety outcomes of dulaglutide by baseline HbA1c: A post hoc analysis of the REWIND trialEdward Franek, Hertzel C Gerstein, Matthew C Riddle, et al.
Diabetes, Obesity & Metabolism|May 13, 2022
Effect of once-weekly semaglutide versus thrice-daily insulin aspart, both as add-on to metformin and optimized insulin glargine treatment in participants with type 2 diabetes (SUSTAIN 11): A randomized, open-label, multinational, phase 3b trialMonika Kellerer, Margit Staum Kaltoft, Jack Lawson, et al.
Pageof 631